Ajaya Bio is a preclinical-stage biotechnology company engineering precision bispecific antibodies to treat autoimmune and oncology indications that lack curative options. Founded by scientist and veteran Dr. Mohit Sachdeva, Ajaya Bio has developed the proprietary protein-engineering platform, enabling modular single-chain bispecifics with tunable linkers to enhance potency, safety, and manufacturability.

Ajaya’s lead program targets refractory rheumatoid arthritis, aiming to deliver durable remission through selective immune cell engagement while avoiding broad immunosuppression. With early support from Ben Franklin Technology Partners, BioAdvance, and NCI-STEP, Ajaya Bio is advancing toward in-vivo proof-of-concept and IND-enabling studies.

Rooted in fearless innovation and disciplined execution, Ajaya Bio’s mission is to transform chronic disease management into lasting cures.

Sector: Healthcare

Industry: Bio-Technology

Status: Active